Key Principles and Recommended Regimens for First-line Antiretroviral Therapy

  • Author: Paul E. Sax, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 2/20/19 (What's New)

Summary

  • Genotypic resistance testing for reverse transcriptase and protease mutations is recommended for all patients newly diagnosed with HIV infection, even if treatment is not immediately initiated[DHHS ART; IAS-USA ART; EACS ART]
  • Resistance-associated mutations present at baseline may be associated with higher rates of virologic failure of those regimens, particularly for NNRTIs[Borroto-Esoda 2007; Kuritzkes 2008]

Action required

Keywords: Initial Antiretroviral Therapy, Resistance Testing

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.